secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cibus, Inc. (CBUS)
CIK:        0001705843
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001628280-24-012521
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cibus Q4 net loss $277M on $249M goodwill impairment; cash $32.7M
-----------------------------------------------------------------

- Net loss $277.2M ($12.59/share) vs $2.8M prior year, driven by $249.4M non-cash goodwill and intangible impairment.
- Cash $32.7M at Dec 31, 2023; expects to fund operations into early Q3 2024.
- R&D expense $14.2M, SG&A $6.8M, both up significantly from prior year due to merger and headcount.
- Business progress: PSR in Canola transferred to 10 customers; HT traits in Rice with Bayer, Nutrien, Nuseed, Interoc.
- EU Parliament vote supporting new genomic techniques; opened gene editing production facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1705843/000162828024012521/0001628280-24-012521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1705843/000162828024012521/cbus-20240321.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-012521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer